Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19
| Autor: | Tim Janssen, Bryan Hartzler, Bryan R. Garner, Elizabeth L. Ball, Kimberly R. Yap, Sara J. Becker, Julia Yermash, Robert Rosales |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Ethnic group Medicine (miscellaneous) Disparities Article Inequity Naloxone Ethnicity Medicine Humans Cluster randomised controlled trial Psychiatry Pandemics Minority Groups Response rate (survey) Harm reduction business.industry SARS-CoV-2 COVID-19 Health Inequities Opioid use disorder medicine.disease Opioid-Related Disorders Health equity United States Outreach Opioids Psychiatry and Mental health Clinical Psychology Ethnic and Racial Minorities Pshychiatric Mental Health business medicine.drug |
| Zdroj: | Journal of Substance Abuse Treatment |
| ISSN: | 1873-6483 |
| Popis: | Introduction The COVID-19 pandemic collided with the opioid epidemic and longstanding health inequities to exacerbate the disproportionate harms experienced by persons with opioid use disorder (OUD) who self-identify as from racial and ethnic minority groups. Disrupted access to harm reduction services (e.g., naloxone, sterile syringes, recovery support) is one pathway whereby COVID-19 might exacerbate health disparities. We tested the hypothesis that persons receiving medication for opioid use disorder (MOUD) who self-identify as from racial/ethnic minority groups would experience more disruptions in access to harm reduction services than persons identifying as non-Hispanic White, even when controlling for severity of opioid use and sociodemographics (e.g., education, income, biological sex, age). Methods Analyses used data from a cluster randomized trial that had enrolled 188 patients, all of whom had provided baseline data on sociodemographics and severity of opioid use, across eight opioid treatment programs. Data collectors re-contacted participants between May and June 2020 and 133 (71% response rate) agreed to complete a survey about access to harm reduction services. Results Twenty-six respondents (20%) identified as from racial/ethnic minority groups (predominantly Black, Hispanic, and/or biracial). Between 7% and 27% of respondents reported disrupted access to harm reduction services. Logistic regressions indicated that persons identifying as from racial/ethnic minority groups were 8–10 times more likely than persons identifying as non-Hispanic White to report reduced access to naloxone and sterile syringes (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect